2 recruiting, 1 active not recruiting. 3 Phase 3.
By phase and status
Follow Nemtabrutinib: new trials by email Literature Review of Nemtabrutinib trials Research Report on Nemtabrutinib
Trials (filtered) newest first · largest first
All 3 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Nemtabrutinib, Ibrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | 1200 | 2023-12-13 | 2026-10-13 |
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Nemtabrutinib, Venetoclax, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic | Phase 3 | Recruiting | 735 | 2023-08-08 | 2026-10-15 |
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Nemtabrutinib, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | 300 | 2023-03-16 | 2026-03-16 |
Conditions studied
Leukemia, Lymphocytic, Chronic, B-Cell (3)
Sponsors
Merck Sharp & Dohme LLC (3)
Countries
Australia (3) · Brazil (3) · Chile (3) · Colombia (3) · Mexico (3) · South Africa (3) · Taiwan (3) · Turkey (Türkiye) (3) · United States (3) · Belgium (2) · Canada (2) · China (2) · Denmark (2) · Germany (2) · Greece (2)
Results publications
PMID 41363770